Precision BioSciences, Inc.
DTIL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | -0.00 | 0.54 | -0.03 |
| FCF Yield | -23.38% | -43.70% | -0.43% | -72.14% |
| EV / EBITDA | -1.00 | -0.61 | -224.79 | 1.80 |
| Quality | ||||
| ROIC | -27.22% | -22.28% | -19.50% | -20.03% |
| Gross Margin | 0.00% | -3,766.67% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.70 | 0.86 | 0.93 | 1.05 |
| Growth | ||||
| Revenue 3-Year CAGR | -76.28% | -69.96% | 18.72% | 39.88% |
| Free Cash Flow Growth | 24.75% | -6.05% | -1.79% | -215.58% |
| Safety | ||||
| Net Debt / EBITDA | 1.99 | 1.46 | 2.43 | 3.37 |
| Interest Coverage | 60.14 | -61.11 | -62.46 | -63.38 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 27.69 | 28,505.04 | 12.41 | 239.53 |